心通醫療-B(02160.HK)中期收入增長121.8 虧損收窄至7010萬元
格隆匯8月29日丨心通醫療-B(02160.HK)公佈，截至2021年6月30日止六個月，公司錄得收入人民幣8620萬元，較截至2020年6月30日止六個月增長121.8%。公司的所有收入均來自已自2019年8月起在中國商業化的VitaFlow的銷售。
期間錄得虧損人民幣7010萬元，而截至2020年6月30日止六個月則錄得虧損人民幣1.22億元。該減少乃主要由於(i)在商業化VitaFlow方面取得進展而令收入大幅增加；(ii)收入增加及生產成本有效控制帶來的毛利大幅提升及(iii)融資成本及其他經營成本因截至2020年6月30日止六個月列賬的若干成本項目為一次性及非經常性而減少所致。
2021年上半年，集團實現持續高速的收入增長，主要得益於第一代TAVI產品VitaFlow銷售量的快速提升。憑藉其獨特的產品設計和優異的臨牀表現，以及市場和銷售團隊的持續努力，醫院覆蓋進一步擴大，在中國部分省市及多家核心醫院佔據市場領先地位，市場份額顯著提升。
與此同時，集團已建立涵蓋TAVI產品、TMV產品、TTV產品、外科瓣膜產品和手術配件等產品的戰略性研發佈局，各大研發項目有序推進，為集團高速健康發展提供持續動能。此外，集團在海外市場完成VitaFlow首例商業植入，開啟全球業務新篇章。隨着產品海外臨牀註冊的推進，藉助微創醫療品牌在全球的知名度及微創醫療集團的現有銷售網絡，公司將持續擴大海外業務版圖，為實現全球業務佈局打下堅實的基礎。
截至2021年6月30日，公司在中國擁有103項專利，包括24項發明專利、72項實用新型專利和7項工業設計。截至同日，公司亦在中國擁有88項待批核的專利申請，包括77項發明專利及11項實用新型專利。為推動公司進入海外市場的策略，公司亦在日本、瑞士、葡萄牙、英國、意大利、德國、法國、西班牙、美國、韓國、澳大利亞及巴西等國家擁有70項專利。公司擁有或申請的所有專利均與公司的產品或在研產品的技術相關，且由內部研發團隊自主研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
